Crucially for the development on novel ALS therapeutics, our data suggest that the detection in blood of epitope‐specific Nf and poly‐(GP) DPR Abs/ICs could provide more easily accessible biomarkers for the selection of faster progressing and C9+ve ALS cases in clinical trials targeting these sub‐sets of ALS patients.15 Here, C9 is linked to amyotrophic lateral sclerosis.